We are studying the effects and safety of a personalized dose of botulinum toxin type A for individuals with severe spasticity. This trial aims to see how well it works for managing symptoms in the upper and lower limbs.
We are studying whether inhaled sevoflurane improves breathing and safety in ICU patients at risk for ARDS compared to standard sedation methods. This research may help us understand better sedation options for these vulnerable patients.
We are studying whether acetylsalicylic acid can lower the risk of stroke and improve cognitive function in patients undergoing treatment for unruptured brain aneurysms. This trial compares ASA with a placebo to assess its safety and effectiveness.
We are studying whether oxytocin is as safe as prostaglandins for inducing labor in women with an unfavorable cervix. This trial will help us understand the risks and benefits of both methods.
We are investigating how effective Daratumumab is for patients with Monoclonal Gammopathy of Renal Significance in Finland. This study aims to understand its potential benefits for kidney health.
We are exploring a new approach to select between two chemotherapy options for patients with metastatic colorectal cancer. This study will help us understand how well these treatments work and their potential side effects.
We are studying how proton pump inhibitors affect the success of endoscopic sleeve gastroplasty in people seeking weight loss. We also want to learn about their effects on quality of life and metabolic health.
We are testing a new treatment using engineered immune cells for people with severe autoimmune diseases that haven't improved with standard therapies. This study aims to see if this approach can help manage their condition.
We are studying a new treatment using stem cells from umbilical cord tissue for people with cartilage damage in the knee. The trial aims to evaluate the safety and effectiveness of this approach.
We are studying whether N-Acetyl-L-Leucine can improve symptoms and quality of life for people with Ataxia-Telangiectasia. The trial will also assess the safety of this treatment.
We are studying whether early treatment with dexamethasone can help reduce serious complications and death in patients with severe burns. This trial will also look at its effects on infections and recovery times.
We are studying whether using tacrolimus alone can reduce infection risks and improve quality of life for elderly patients after a kidney transplant. This trial compares it to the standard triple medication regimen.
We are testing a new medication, TAK-360, for people with idiopathic hypersomnia to see if it helps reduce excessive daytime sleepiness and improve overall condition. The study will also monitor the safety and tolerability of the treatment.
We are investigating whether Vericiguat can improve physical function and reduce fatigue in individuals with post-COVID-19 syndrome compared to a placebo. This study aims to assess various aspects of health and safety related to the treatment.
We are exploring whether giving chemotherapy before surgery helps improve survival for patients with resectable pancreatic head cancer compared to surgery alone. This study aims to find better treatment strategies to reduce early mortality.
We are investigating whether ibuzatrelvir can help reduce symptoms and prevent severe illness in non-hospitalized adults and adolescents with COVID-19. This study compares the medication to a placebo to see how effective it is.
We are studying a new treatment combination for patients with advanced non-squamous lung cancer who have not responded to standard therapies. The trial will evaluate safety and early signs of effectiveness.
We are evaluating a new oral medication for spasticity in people with multiple sclerosis. The study aims to see if it improves symptoms and overall function compared to a placebo.
We are studying whether psilocybin can quickly improve depression in people with cancer compared to ketamine and midazolam. The trial will also look at its effects on quality of life and overall well-being.
We are testing a new antibody treatment for patients with solid cancers to see how well it works alone and with other therapies. This study aims to understand its safety and potential benefits.